Altogether, these findings support further clinical evaluation of CDK2 inhibitors like Dinaciclib administered in combination with endocrine therapy as a potentially new treatment strategy against ESR1 mutation expressing breast cancers. This evidence concerns the gene CDK2 and breast carcinoma.